Howard I Scher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5646206/publications.pdf

Version: 2024-02-01

171 papers	45,860 citations	14614 66 h-index	5663 162 g-index
178 all docs	178 docs citations	178 times ranked	39528 citing authors

#	Article	IF	Citations
1	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine, 2012, 367, 1187-1197.	13.9	3,847
2	Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell, 2010, 18, 11-22.	7.7	3,151
3	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
4	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
5	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
6	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine, 2014, 371, 424-433.	13.9	2,456
7	Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2008, 14, 6302-6309.	3.2	1,975
8	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159.	0.8	1,960
9	Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of Clinical Oncology, 2016, 34, 557-565.	0.8	1,746
10	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 700-712.	5.1	1,280
11	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
12	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	13.5	1,184
13	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	0.8	1,089
14	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1â€“2 study. Lancet, The, 2010, 375, 1437-1446.	6.3	972
15	Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis. Journal of Clinical Oncology, 2005, 23, 8253-8261.	0.8	932
16	Rapid screening for psychologic distress in men with prostate carcinoma. , 1998, 82, 1904-1908.		867
17	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	3.3	839
18	Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy. Journal of Clinical Oncology, 1999, 17, 3173-3181.	0.8	658

#	Article	IF	Citations
19	Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer, 1989, 64, 2448-2458.	2.0	654
20	Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium. Journal of Urology, 1985, 133, 403-407.	0.2	630
21	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	9.4	601
22	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology, The, 2009, 10, 233-239.	5.1	558
23	Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1441.	3.4	535
24	M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium. Journal of Urology, 1988, 139, 461-469.	0.2	517
25	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	3.4	426
26	Phase II Study of Lutetium-177â€“Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 5182-5191.	3.2	370
27	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1348-1355.	0.8	343
28	High-risk prostate cancerâ€”classification and therapy. Nature Reviews Clinical Oncology, 2014, 11, 308-323.	12.5	340
29	Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer, 1994, 73, 2791-2802.	2.0	320
30	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
31	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286
32	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
33	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	0.8	267
34	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, The, 2012, 13, 1210-1217.	5.1	254
35	Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Medicine, 1998, 4, 50-57.	15.2	249
36	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 2004, 11, 459-476.	1.6	212

#	Article	IF	Citations
37	Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder Lesion. Journal of Urology, 1988, 139, 470-474.	0.2	211
38	Feedback Suppression of PI3KÎ± Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3KÎ². Cancer Cell, 2015, 27, 109-122.	7.7	203
39	Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1179.	3.4	190
40	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology, 2018, 36, 572-580.	0.8	187
41	Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE, 2015, 10, e0139440.	1.1	181
42	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	3.2	177
43	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1344.	3.4	169
44	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285.	3.2	163
45	Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma. Journal of Clinical Oncology, 1999, 17, 2546-2546.	0.8	152
46	Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. European Urology, 2017, 71, 874-882.	0.9	150
47	The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell, 2019, 36, 139-155.e10.	7.7	131
48	HER-2 profiling and targeting in prostate carcinoma. Cancer, 2002, 94, 980-986.	2.0	128
49	Prostate Cancer Clinical Trial End Points: â€œRECISTâ€ing a Step Backwards. Clinical Cancer Research, 2005, 11, 5223-5232.	3.2	126
50	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363.	0.8	120
51	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2016, 22, 1510-1519.	3.2	117
52	First-in-Human Imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine, 2016, 57, 1858-1864.	2.8	116
53	Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Cancer, 2000, 88, 1671-1678.	2.0	112
54	Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Research, 2017, 77, 5687-5698.	0.4	112

#	Article	IF	Citations
55	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2020, 26, 3230-3238.	3.2	112
56	Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. Clinical Chemistry, 2019, 65, 87-99.	1.5	109
57	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. European Urology, 2020, 78, 822-830.	0.9	99
58	Positron Emission Tomography/Computed Tomographyâ€“Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217.	3.4	93
59	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366.	1.5	93
60	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	5.1	90
61	Expression of Transforming Growth Factor-Î± and the Epidermal Growth Factor Receptor in Human Prostate Tissues. Journal of Urology, 1994, 152, 2120-2124.	0.2	89
62	A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle. Angewandte Chemie - International Edition, 1999, 38, 563-566.	7.2	87
63	Validation and clinical utility of prostate cancer biomarkers. Nature Reviews Clinical Oncology, 2013, 10, 225-234.	12.5	83
64	Identification and characterization of circulating prostate carcinoma cells. Cancer, 2000, 88, 2787-2795.	2.0	82
65	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, .	6.0	75
66	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. Clinical Cancer Research, 2007, 13, 2707-2713.	3.2	73
67	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology, 2020, 78, 671-679.	0.9	72
68	The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer. Clinical Cancer Research, 2007, 13, 1488-1492.	3.2	67
69	Analytic and Clinical Validation of a Prostate Cancerâ€“Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival. European Urology, 2014, 65, 1191-1197.	0.9	66
70	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1.	0.8	66
71	Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor: A possible new recombinant granulocyte colony-stimulating factor toxicity. Cancer, 1992, 70, 2699-2702.	2.0	64
72	Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer. Journal of Clinical Oncology, 2000, 18, 1936-1941.	0.8	64

#	Article	IF	Citations
73	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28.	1.1	63
74	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell, 2017, 32, 792-806.e7.	7.7	61
75	A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investigational New Drugs, 2018, 36, 458-467.	1.2	61
76	Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. European Urology, 2020, 77, 170-177.	0.9	60
77	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology, 2017, 102, 164-172.	0.5	52
78	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
79	Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Extravesical Urinary Tract Tumors. Journal of Urology, 1988, 139, 475-477.	0.2	48
80	Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer, 2000, 89, 1329-1348.	2.0	48
81	Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics. Clinical Cancer Research, 2011, 17, 6634-6640.	3.2	46
82	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clinical Cancer Research, 2017, 23, 1967-1973.	3.2	46
83	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 694.	3.4	46
84	Prostate carcinoma. Cancer, 2003, 97, 758-771.	2.0	45
85	Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer, 1992, 70, 2870-2878.	2.0	44
86	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. European Urology, 2019, 75, 929-937.	0.9	41
87	Chemotherapy for urothelial tract malignancies: Breaking the deadlock. Journal of Surgical Oncology, 1992, 8, 316-341.	1.4	40
88	Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. , 1998, 7, 129-132.		40
89	Long-term Safety and Antitumor Activity in the Phase 1â€“2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European Urology, 2015, 68, 795-801.	0.9	39
90	Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncology, 2020, 6, e193332.	3.4	39

#	Article	IF	Citations
91	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e15-530.e21.	0.8	38
92	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of Nuclear Medicine, 2019, 60, 1517-1523.	2.8	38
93	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	3.0	38
94	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer, 1990, 65, 2465-2470.	2.0	37
95	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629.	5.8	37
96	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2926-2937.	0.8	36
97	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. European Urology, 2015, 67, 310-318.	0.9	35
98	Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy. Journal of Urology, 2017, 198, 65-70.	0.2	32
99	The collection of indirect and nonmedical direct costs (COIN) form. Cancer, 2001, 91, 841-853.	2.0	31
100	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. Clinical Genitourinary Cancer, 2015, 13, e305-e309.	0.9	30
101	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. European Urology Oncology, 2019, 2, 605-616.	2.6	30
102	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1167-1179.	1.5	28
103	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	3.2	28
104	Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. Molecular and Cellular Proteomics, 2014, 13, 3082-3096.	2.5	27
105	Everolimus combined with gefitinib in patients with metastatic castrationâ€resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer, 2015, 121, 3853-3861.	2.0	27
106	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer, 1993, 72, 3313-3317.	2.0	26
107	Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer. Cancer Research, 2020, 80, 4892-4903.	0.4	26
108	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	3.6	26

#	Article	IF	Citations
109	A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 171-178.e2.	0.9	25
110	Do Patients With AR-V7â€“Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. European Urology, 2017, 71, 4-6.	0.9	24
111	Internalization of secreted antigenâ€“targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine, 2016, 8, 367ra167.	5.8	23
112	Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in phase II trial of flutamide. Cancer, 1984, 54, 477-481.	2.0	22
113	Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer Chemotherapy and Pharmacology, 1986, 18, 24-26.	1.1	21
114	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 4077-4088.	3.2	21
115	Biomarker development in the context of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 295-301.	0.8	20
116	Reproducibility and Repeatability of Semiquantitative ¹⁸F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of Nuclear Medicine, 2018, 59, 1516-1523.	2.8	20
117	Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. Journal of Nuclear Medicine, 2021, 62, 1050-1056.	2.8	19
118	Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. , 1998, 7, 129.		19
119	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. JAMA Oncology, 2020, 6, 217.	3.4	18
120	Controversies in Treatment of Small Cell Carcinoma of the Lung. Cancer Investigation, 1985, 3, 367-387.	0.6	17
121	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptorâ€“Axis Imaging. Journal of Nuclear Medicine, 2016, 57, 73S-78S.	2.8	16
122	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	1.2	16
123	A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer Chemotherapy and Pharmacology, 2000, 46, 79-83.	1.1	15
124	Immune-mediated thrombocytopenia secondary to suramin. Cancer, 1993, 71, 851-854.	2.0	14
125	Picking the winners in a sea of plenty. Clinical Cancer Research, 2002, 8, 400-4.	3.2	14
126	Optimizing the future: how mathematical models inform treatment schedules for cancer. Trends in Cancer, 2022, 8, 506-516.	3.8	14

#	Article	IF	Citations
127	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 2022, 170, 296-304.	1.3	14
128	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	3.2	13
129	PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy. Journal of Urology, 2020, 203, 344-350.	0.2	12
130	Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. Journal of Urology, 2022, 207, 1010-1019.	0.2	12
131	INTERSTITIAL PNEUMONITIS FOLLOWING BICALUTAMIDE TREATMENT FOR PROSTATE CANCER. Journal of Urology, 1998, 160, 131-131.	0.2	11
132	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European Urology Oncology, 2021, 4, 543-552.	2.6	11
133	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171.	0.5	11
134	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology, 2012, 30, 25-25.	0.8	11
135	Detectable tumor cells in the blood and bone marrow. , 1998, 83, 394-398.		10
136	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 507-516.	2.0	10
137	Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling. Clinical Chemistry, 2020, 66, 3-5.	1.5	8
138	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology, 2018, 15, 168-182.	12.5	7
139	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of Clinical Oncology, 2019, 37, 2184-2186.	0.8	7
140	Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 338-348.	1.2	7
141	Development of an immunofluorescent AR-V7 circulating tumor cell assay â€“ A blood-based test for men with metastatic prostate cancer. Journal of Circulating Biomarkers, 2020, 9, 13-19.	0.8	7
142	The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3603-3617.	3.2	7
143	Experimental Studies and Phase II Trial of Bisantrene in Advanced Urothelial Malignancies. Cancer Investigation, 1985, 3, 123-127.	0.6	6
144	Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies. JCO Oncology Practice, 2022, 18, e938-e947.	1.4	5

#	Article	IF	Citations
145	CHAARTED/GETUG 12â€"docetaxel in non-castrate prostate cancers. Nature Reviews Clinical Oncology, 2015, 12, 687-688.	12.5	4
146	Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). British Journal of Cancer, 2018, 119, 1041-1043.	2.9	4
147	Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer. Investigational New Drugs, 2021, 39, 499-508.	1.2	4
148	Rapid screening for psychologic distress in men with prostate carcinoma. , 1998, 82, 1904.		4
149	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	0.9	4
150	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clinical Cancer Research, 2022, 28, 860-869.	3.2	4
151	Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 147-147.	0.8	3
152	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European Urology Open Science, 2021, 34, 70-78.	0.2	3
153	Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. Prostate, 2022, , .	1.2	3
154	Building on Prostate Cancer Working Group 2 to Change the Paradigm from Palliation to Cure. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e204-e212.	1.8	2
155	Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. ESMO Open, 2020, 5, e000943.	2.0	2
156	Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).. Journal of Clinical Oncology, 2015, 33, 169-169.	0.8	2
157	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Clinical Genitourinary Cancer, 2022, 20, 69-79.	0.9	2
158	Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation. Molecular Cancer Therapeutics, 2022, 21, 831-843.	1.9	2
159	Defining new standards of care for men with prostate cancer. Lancet, The, 2016, 387, 1135-1137.	6.3	1
160	Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer. JAMA Oncology, 2017, 3, 1673.	3.4	1
161	Identification and characterization of circulating prostate carcinoma cells. , 2000, 88, 2787.		1
162	The collection of indirect and nonmedical direct costs (COIN) form. Cancer, 2001, 91, 841-853.	2.0	1

#	Article	IF	Citations
163	HER-2 profiling and targeting in prostate carcinoma. , 2002, 94, 980.		1
164	Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, , .	0.9	1
165	Current management of hormone-refractory prostate cancer. Clinical Advances in Hematology and Oncology, 2004, 2, 724-6.	0.3	1
166	Intracavitary birdcage resonator: Applications to the human prostate. Journal of Magnetic Resonance Imaging, 1995, 5, 365-368.	1.9	0
167	A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 269.	0.8	0
168	A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 115.	0.8	0
169	Author Reply. Urology, 2017, 102, 172.	0.5	0
170	Reply to C. Ren et al. Journal of Clinical Oncology, 2018, 36, 2354-2356.	0.8	0
171	Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Testâ€"In Reply. JAMA Oncology, 2019, 5, 434.	3.4	0